...
首页> 外文期刊>Toxicology Reports >Use of Bidens pilosa L. (Asteraceae) and Curcuma longa L. (Zingiberaceae) to treat intestinal mucositis in mice: Toxico-pharmacological evaluations
【24h】

Use of Bidens pilosa L. (Asteraceae) and Curcuma longa L. (Zingiberaceae) to treat intestinal mucositis in mice: Toxico-pharmacological evaluations

机译:Bidens pilosa L.(Asteraceae)和Curcuma longa L.(Zingiberaceae)在治疗小鼠肠道粘膜炎中的用途:毒理学评价

获取原文
           

摘要

Introduction: Several studies towards the development of an effective treatment for intestinal mucositis have been reported, since this condition represents a major problem in clinical oncology practice due to cytotoxic effects of chemotherapy. However standardized protocols and universally accepted treatment options are yet to be established. Objectives: Given above, this study evaluated the protective effects of a mucoadhesive formulation containing both Bidens pilosa L. (Asteraceae) (BP) and curcuminoids from Curcuma longa L. (Zingiberaceae) (CL) on intestinal mucositis induced by 5-fluoruoacil (5-FU) in mice. Results: As expected, animals only treated with 5-FU (200mg/kg) showed a significant reduction of 60.3 and 42.4% in villi and crypts size, respectively, when compared to control. On the other hand, the proposed therapeutic/prophylactic treatment with mucoadhesive formulations managed to reduce histopathologic changes in mice bearing mucositis, especially at 125mg/kg BP+15mg/kg CL dose. The formulation promoted an increase of 275.5% and 148.7% for villi and crypts size, respectively. Moreover, chemotherapy-related weight loss was reduced by 7.4% following the treatment. In addition, an increase of 10 and 30.5% in red and white blood cells was observed when compared to 5-FU group. Furthermore, treatments with the mucoadhesive formulation containing BP/CL up modulated Ki-67 and Bcl-2 expression while reduced pro-apoptotic regulator Bax. The formulation also modulated inflammatory response triggered by 5-FU through reduction of 68% of myeloperoxidase activity and a 4-fold increase in anti-inflammatory IL-10 levels. In parallel, the oxidative stress via lipid peroxidation was reduced as indicated by decrease of 63% of malondialdehyde concentrations. Additionally, the new formulation presented low acute oral systemic toxicity, being classified in the category 5 (2000mg/kg
机译:简介:由于化学疗法的细胞毒性作用,这种情况代表了临床肿瘤学实践中的主要问题,因此已经报道了几项研究,旨在开发一种有效治疗肠粘膜炎的方法。然而,尚未建立标准化的方案和普遍接受的治疗方案。目的:鉴于上述情况,本研究评估了同时含有Bidens pilosa L.(Asteraceae)(BP)和姜黄姜黄(Zingiberaceae)(CL)姜黄素的粘膜粘附制剂对5-氟尿嘧啶引起的肠粘膜炎的保护作用(5 -FU)。结果:与预期相比,仅用5-FU(200mg / kg)处理的动物的绒毛和隐窝大小分别显着减少了60.3%和42.4%。另一方面,拟议的用粘膜粘附制剂进行的治疗/预防治疗设法减轻了患有粘膜炎的小鼠的组织病理学变化,尤其是在125mg / kg BP + 15mg / kg CL剂量下。该配方分别促进绒毛和隐窝大小增加275.5%和148.7%。此外,治疗后与化疗有关的体重减轻减少了7.4%。另外,与5-FU组相比,观察到红细胞和白细胞分别增加了10.5%和30.5%。此外,用含BP / CL的粘膜粘着剂制剂处理可上调Ki-67和Bcl-2表达,同时降低促凋亡调节剂Bax。该制剂还通过降低68%的髓过氧化物酶活性和将抗炎IL-10水平提高4倍来调节由5-FU触发的炎症反应。同时,通过降低脂质过氧化引起的氧化应激,表明丙二醛浓度降低了63%。另外,该新制剂表现出低的急性口服全身毒性,被归类于全球协调分类系统的类别5(2000mg / kg <LD″ 5″ 0 <5000mg / kg)。结论:这项研究显示了BP / CL粘膜粘附制剂在治疗5-FU引起的肠道粘膜炎中的潜在潜力。考虑到新药开发的前景,正在进行临床研究以更好地理解这种创新制剂在治疗粘膜炎中的保护作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号